



COPY OF PAPERS  
ORIGINALLY FILED

Attorney's Docket No.: 08952-008001 / UMA 00-19

# 9/18  
JLM  
RECEIVED  
SEP 10 2002  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Elizabeth S. Stuart et al.

Art Unit : 1645

Serial No. : 09/827,490

Examiner : Vanessa L. Ford

Filed : April 6, 2001

Title : CHLAMYDIAL GLYCOLIPID VACCINES

Commissioner for Patents  
Washington, D.C. 20231

RESPONSE TO OFFICE ACTION DATED MARCH 26, 2002

Please amend the application as indicated below and consider the following remarks.

In the Specification:

Amend the paragraph at page 1, lines 22 to 27, as follows:

A' The invention is based on the discovery of an effective chlamydial vaccine based on oligosaccharides derived from one or more chlamydial glycolipids, such as the chlamydial glycolipid exoantigen (GLXA; see, e.g., U.S. Patent No. 5,840,297). These oligosaccharides, which are cleaved from naturally occurring glycolipids or chemically synthesized, are then covalently linked to a carrier group to form a composition that can be used as a chlamydia vaccine.

Amend the paragraph at page 6, lines 13 to 29, as follows:

A<sup>2</sup> Glycolipids from *Chlamydia* can be isolated by any method known in the art, or by the methods described below. For example, cells (e.g., McCoy cells [a mouse fibroblast cell line], the mouse macrophage cell line J774A.1, or HeLa 229 cells) can be infected with *Chlamydia trachomatis* (B serovar) *in vitro* at an MOI of 10. At 24 hours post-infection 100 U/ml of penicillin are added to increase production of GLXA into the supernatant. GLXA is a

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, Washington, D.C. 20231.

Date of Deposit

August 26, 2002

Signature

Karen Lacerda

Typed or Printed Name of Person Signing Certificate

Karen Lacerda